MLANA and melanoma: Despite obvious tumor shrinkage, on-target AEs have been observed in a clinical trial using an avidity-increased HLA-A*0201-restricted TCR specific for the melanoma-associated antigens MART-1 and gp100, which are also expressed substantially in normal melanocytes and pigmented tissues, resulting in skin rash, hearing loss and uveitis [27].